BerandaALNY • NASDAQ
add
Alnylam Pharmaceuticals, Inc.
$428,14
Setelah Jam Perdagangan Normal:(0,00%)0,00
$428,14
Tutup: 6 Agu, 16.31.45 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$418,91
Rentang hari
$415,00 - $428,69
Rentang tahun
$205,87 - $428,69
Kapitalisasi pasar
56,12Â M USD
Volume Rata-Rata
1,12Â jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 773,69Â jt | 17,26% |
Biaya operasional | 646,94Â jt | 19,24% |
Laba bersih | -66,28Â jt | -292,43% |
Margin laba bersih | -8,57 | -234,77% |
Penghasilan per saham | 0,32 | -42,86% |
EBITDA | -2,26Â jt | -103,54% |
Tarif pajak efektif | -87,45% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 2,86Â M | 8,87% |
Total aset | 4,57Â M | 13,88% |
Total liabilitas | 4,32Â M | 7,54% |
Total ekuitas | 250,59 jt | — |
Saham yang beredar | 131,08 jt | — |
Harga terhadap nilai buku | 219,32 | — |
Tingkat pengembalian aset | -0,92% | — |
Tingkat pengembalian modal | -1,39% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -66,28Â jt | -292,43% |
Kas dari operasi | 153,73Â jt | 23,82% |
Kas dari investasi | -141,38Â jt | -516,56% |
Kas dari pembiayaan | 53,76Â jt | -59,12% |
Perubahan kas bersih | 93,61Â jt | -67,32% |
Arus kas bebas | 135,38Â jt | -50,37% |
Tentang
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Didirikan
14 Jun 2002
Situs
Karyawan
2.230
